Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD ... on its earlier accelerated approval with a very narrow label covering ambulatory boys aged between four and five.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback